Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 19/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terconazole SCHEMBL7601910 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL23165 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL4924542 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL5008913 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL29388408 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL17493426 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL4923831 | 0.99 | CYP3A4 (0.98) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL9043676 | 0.99 | CYP3A4 (0.98) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL6233263 | 0.94 | CYP3A4 (0.89) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL1066299 | 0.94 | CYP3A4 (0.89) | CYP3A4LMNACYP51A1FYNNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115955967-B | Vaginal gel | 国家医疗用品有限责任公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-115955967-A | Vaginal gel | 国家医疗用品有限责任公司 | 2023-04-11 | — | — | CN | disclosed |
| WO-2021151964-A1 | USE OF AZOLE COMPOUNDS TO STIMULATE THE IMMUNE SYSTEM AND AS INHIBITORS FOR S-PLA2GIB | DIACCURATE (FR) | 2021-08-05 | — | — | WO | disclosed |
| EP-3858357-A1 | USE OF AZOLE COMPOUNDS TO STIMULATE THE IMMUNE SYSTEM AND AS INHIBITORS FOR S-PLA2GIB | Diaccurate (FR) | 2021-08-04 | — | — | EP | disclosed |
| US-9839636-B2 | Itraconazole analogues and methods of use thereof | UNIVERSITY OF CONNECTICUT (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170209436-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-27 | — | — | US | disclosed |
| US-20160340346-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340346-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | GLI1, SHH, SMO | CYP3A4 2373/4885LMNA 4777/4885CYP51A1 51/4885 |
| US-20170209436-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | GLI1, SHH, SMO | CYP3A4 2373/4885LMNA 4777/4885CYP51A1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.